A limited sampling strategy for tacrolimus in renal transplant patients

British Journal of Clinical Pharmacology

Volumn 66, Issue 4, 2008, Pages 467-472

  Mathew, Binu S ^a   Fleming, Denise H ^a   Jeyaseelan, Visalakshi ^a   Chandy, Sujith J ^a   Annapandian, V M ^a   Subbanna, P K ^a   John, George T ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Jackknife; Limited sampling strategy; Tacrolimus

Indexed keywords

MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PANGRAF; PREDNISOLONE; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE TITRATION; FEMALE; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MAXIMUM PLASMA CONCENTRATION; MICROPARTICLE ENZYME IMMUNOASSAY; NEPHROTOXICITY; PRIORITY JOURNAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AREA UNDER CURVE; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LINEAR MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SAMPLING STUDIES; TACROLIMUS; TIME FACTORS;

EID: 51649106007     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03251.x     Document Type: Article

References (23)

1. Yoshimura N, Takahara S, Uchida K, Takahashi K, Toma H, Oshima S, Sonoda T, Japanese Tacrolimus Study Group. Safety analysis after tacrolimus immunosuppression in renal transplant recipients in Japan: 5-year results in >1500 patients. Transplant Proc 2005 37: 1764 6.
2. Laskow DA, Vincenti F, Neylan JF, Mendez R, Matas AJ. An open label concentration ranging trial of FK506 in primary kidney transplantation. Transplantation 1996 62: 900 5.
3. Shaw LM, Holt DW, Oellerich M, Meiser B, Van Gelder T. Current issues in therapeutic drug monitoring of mycophenolic acid. Report of a round table discussion. Ther Drug Monit 2001 23: 305 15.
4. Brennan DC, Agha I, Bohl DL, Schnitzler MA, Hardinger KL, Lockwood M, Torrence S, Schuessler R, Roby T, Gaudreault-Keener M, Storch GA. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005 5: 582 94.
5. Ekberg H, Tedesco-Silva H, Demirba A, Vítko S, Nashan B, Gürkan A, Margreiter R, Hugo C, Grinyó JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007 357: 2562 75.
6. Staatz C, Taylor P, Tett S. Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. Nephrol Dial Transplant 2001 16: 1905 9.
7. Jorgensen K, Povlsen J, Madsen S, Madsen M, Hansen H, Pedersen A, Heinsvig E-M, Poulsen J. C2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients. Nephrol Dial Transplant 2002 17: 1487 90.
8. Undre NA, Van Hooff J, Christiaans M, Vanrenterghem Y, Donck J, Heeman U, Kohnle M, Zanker B, Land W, Morales JM, Andrés A, Schäfer A, Stevenson P. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc 1999 31: 296 8.
9. Yolanda A, Leonor P, Carme C, Rosa L, Manuel P, Lluis C. Evaluation of a limited sampling strategy to estimate area under the curve of tacrolimus in adult renal transplant patients. Ther Drug Monit 2005 27: 431 4.
10. Stolk LML, Van Duijnhoven EM, Christiaans MHL, Van Hooff JP. Trough levels of tacrolimus. Ther Drug Monit 2002 24: 573.
11. Wong KM, Shek CC, Chau KF, Li CS. Abbreviated tacrolimus area under the curve monitoring for renal transplant recipients. Am J Kidney Dis 2000 35: 660 6.
12. Kimikawa M, Kamoya K, Toma H, Teraoka S. Effective oral administration of tacrolimus in renal transplant recipients. Clin Transplant 2001 15: 324 9.
13. MacPhee IAM, Spreafico S, Bewick M, Davis C, Eastwood JB, Johnston A, Lee T, Holt DW. Pharmacokinetics of mycophenolate mofetil in patients with end stage renal failure. Kidney International 2000 1164 8.
14. Abbott Laboratories Package Insert IMx System 2005 List no: 3C10.
15. Suarez-Kurtz G, Bozza FA, Vicente FL, Ponte CG, Struchiner CJ. Limited-sampling strategy models for itraconazole and hydroxy-itraconazole based on data from a bioequivalence study. Antimicrob Agents Chemother 1999 43: 134 40.
16. Suarez-Kurtz G, Ribeiro FM, Estrela RCE, Vicenti FL, Struchiner CJ. Limited sampling strategy models for estimating the pharmacokinetic parameters of 4-methylaminoantipyrine, an active metabolite of dipyrone. Braz J Med Biol Res 2001 34: 1475 85.
17. Jeyaseelan L, Rao PSS. Statistical measurements of clinical agreement. Natl Med J India 1992 5: 286 90.
18. Krouwer JS. Why Bland-Altman plots should use X, not (Y + X)/2 when X is a reference method. Stat Med 2008 27: 778 80.
19. Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ 1999 318: 1104 7.
20. Webster A, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus cyclosporine as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005 19: CD003961.
21. Böttiger Y, Brattström C, Tydén G, Säwe J, Groth CG. Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. Br J Clin Pharmacol 1999 48: 445 8.
22. Kuypers Dirk RJ, Kathleen C, Pieter E, Bart M, Yves V. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther 2004 75: 434 47.
23. Mendonza AE, Zahir H, Gohh RY, Akhlaghi F. Tacrolimus in diabetic kidney transplant recipients: pharmacokinetics and application of a limited sampling strategy. Ther Drug Monit 2007 29: 391 8.